Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Andre

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre, Philippe Colin, Christophe Louvet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.
BMC Cancer|July 27, 2016
Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programAntoine Adenis, Christelle de la Fouchardiere, Bernard Paule, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.
Journal for Immunotherapy of Cancer|May 19, 2025
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL studyLeonard Depotte, Paula Nay, Christophe Borg, et al.
The Lancet. Oncology|January 18, 2017
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyTamas Hickish, Thierry Andre, Lucjan Wyrwicz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 7, 2018
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)Pierre Michel, Valerie Boige, Thierry Andre, et al.
Journal for Immunotherapy of Cancer|February 13, 2021
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancerRomain Cohen, Vincent Jonchère, Christelle De La Fouchardière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre, Philippe Colin, Christophe Louvet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.
BMC Cancer|July 27, 2016
Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programAntoine Adenis, Christelle de la Fouchardiere, Bernard Paule, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.
Journal for Immunotherapy of Cancer|May 19, 2025
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL studyLeonard Depotte, Paula Nay, Christophe Borg, et al.
The Lancet. Oncology|January 18, 2017
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyTamas Hickish, Thierry Andre, Lucjan Wyrwicz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 7, 2018
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)Pierre Michel, Valerie Boige, Thierry Andre, et al.
Journal for Immunotherapy of Cancer|February 13, 2021
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancerRomain Cohen, Vincent Jonchère, Christelle De La Fouchardière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Pageof 6